Marcel Flendrie

1.0k total citations
34 papers, 731 citations indexed

About

Marcel Flendrie is a scholar working on Nephrology, Rheumatology and Surgery. According to data from OpenAlex, Marcel Flendrie has authored 34 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Nephrology, 18 papers in Rheumatology and 9 papers in Surgery. Recurrent topics in Marcel Flendrie's work include Gout, Hyperuricemia, Uric Acid (18 papers), Urticaria and Related Conditions (10 papers) and Rheumatoid Arthritis Research and Therapies (7 papers). Marcel Flendrie is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (18 papers), Urticaria and Related Conditions (10 papers) and Rheumatoid Arthritis Research and Therapies (7 papers). Marcel Flendrie collaborates with scholars based in Netherlands, United States and United Kingdom. Marcel Flendrie's co-authors include M.C.W. Creemers, Piet L. C. M. van Riel, Piet LCM van Riel, E.M.G.J. de Jong, Jaap Fransen, Maria T. E. Hopman, Sibrand Houtman, Jan T. Groothuis, Karin H. L. Gerrits and Alfons A den Broeder and has published in prestigious journals such as PLoS ONE, Journal of Applied Physiology and Journal of Clinical Microbiology.

In The Last Decade

Marcel Flendrie

25 papers receiving 710 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marcel Flendrie Netherlands 10 395 180 174 160 97 34 731
Kok Ooi Kong Singapore 16 577 1.5× 259 1.4× 114 0.7× 183 1.1× 98 1.0× 36 870
Sophie Pouplin France 16 516 1.3× 231 1.3× 214 1.2× 78 0.5× 186 1.9× 60 1.1k
María Pilar Cruz-Domínguez Mexico 16 267 0.7× 214 1.2× 66 0.4× 206 1.3× 142 1.5× 64 890
Marion Couderc France 18 469 1.2× 138 0.8× 78 0.4× 83 0.5× 123 1.3× 71 823
Han Joo Baek South Korea 17 583 1.5× 298 1.7× 180 1.0× 54 0.3× 120 1.2× 68 997
Andy Abril United States 18 438 1.1× 96 0.5× 48 0.3× 149 0.9× 195 2.0× 62 941
Geun-Tae Kim South Korea 16 260 0.7× 113 0.6× 61 0.4× 155 1.0× 114 1.2× 49 731
Socorro Méndez‐Martínez Mexico 13 276 0.7× 150 0.8× 54 0.3× 104 0.7× 69 0.7× 64 558
Anestis Mavridis Greece 17 181 0.5× 121 0.7× 166 1.0× 86 0.5× 99 1.0× 32 727
M. Hammoudeh Qatar 15 316 0.8× 144 0.8× 79 0.5× 113 0.7× 46 0.5× 53 614

Countries citing papers authored by Marcel Flendrie

Since Specialization
Citations

This map shows the geographic impact of Marcel Flendrie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcel Flendrie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcel Flendrie more than expected).

Fields of papers citing papers by Marcel Flendrie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcel Flendrie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcel Flendrie. The network helps show where Marcel Flendrie may publish in the future.

Co-authorship network of co-authors of Marcel Flendrie

This figure shows the co-authorship network connecting the top 25 collaborators of Marcel Flendrie. A scholar is included among the top collaborators of Marcel Flendrie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcel Flendrie. Marcel Flendrie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Richette, Pascal, Marcel Flendrie, Leo A. B. Joosten, & Noortje van Herwaarden. (2025). Can Urate Lowering Therapy Be Stopped in Gout? Rationale and Design of Two Large Randomised Trials. 3(1). 2–2.
3.
Mackenzie, Isla S., Marcel Flendrie, Călin D. Popa, et al.. (2025). Ischaemic cardiovascular risk with allopurinol and protective effect of colchicine in gout: a Dutch nationwide pharmaco-epidemiological study. European Journal of Preventive Cardiology. 33(5). 682–690.
4.
5.
Bemt, Bart J. F. van den, et al.. (2024). Support needs of gout patients and suitability of eHealth to address these needs. Rheumatology Advances in Practice. 8(4). rkae125–rkae125. 1 indexed citations
6.
Bemt, Bart J. F. van den, et al.. (2024). Determinants of Self‐Management Behavior in Gout: A Scoping Review. Arthritis Care & Research. 77(4). 534–544.
7.
Leavis, Helen L., Paul Van Daele, Catharina M. Mulders‐Manders, et al.. (2023). Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts. Lara D. Veeken. 63(6). 1656–1663. 16 indexed citations
8.
Vriezekolk, Johanna E, Bart J. F. van den Bemt, Henk Schers, et al.. (2023). Beliefs of rheumatologists and general practitioners on urate lowering therapy: a cross-sectional study. Rheumatology Advances in Practice. 7(2). rkad033–rkad033. 1 indexed citations
9.
10.
Boonen, Annelies, Tim Jansen, Marcel Flendrie, et al.. (2022). Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout. BMC Medical Informatics and Decision Making. 22(1). 95–95. 4 indexed citations
11.
Verhoef, Lise M, Alfons A den Broeder, Wing‐Yee Kwok, et al.. (2022). Effect of metformin use on clinical outcomes and serum urate in gout patients with diabetes mellitus: a retrospective cohort study. BMC Rheumatology. 6(1). 27–27. 4 indexed citations
12.
Bekker, Charlotte L., et al.. (2021). Tele-monitoring flares using a smartphone app in patients with gout or suspected gout: a feasibility study. Rheumatology Advances in Practice. 5(3). rkab100–rkab100. 3 indexed citations
13.
Vandeberg, Lisa, Annemiek J. Linn, Marcel Flendrie, et al.. (2020). Are Health Care Professionals’ Implicit and Explicit Attitudes Toward Conventional Disease‐Modifying Antirheumatic Drugs Associated With Those of Their Patients?. Arthritis Care & Research. 73(3). 364–373. 3 indexed citations
14.
Linn, Annemiek J., Lisa Vandeberg, Liset van Dijk, et al.. (2019). Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence. PLoS ONE. 14(8). e0221290–e0221290. 7 indexed citations
15.
Fransen, Jaap, Wietske Kievit, Marcel Flendrie, et al.. (2012). Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Annals of the Rheumatic Diseases. 72(6). 895–900. 120 indexed citations
16.
Lieshout, Antoine W.T. van, Jaap Fransen, Marcel Flendrie, et al.. (2007). Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases. 66(10). 1334–1338. 25 indexed citations
17.
Flendrie, Marcel, M.C.W. Creemers, & Piet L. C. M. van Riel. (2006). Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Lara D. Veeken. 46(1). 146–149. 18 indexed citations
18.
Flendrie, Marcel, et al.. (2005). Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Research & Therapy. 7(3). R666–76. 202 indexed citations
19.
20.
Hopman, Maria T. E., Jan T. Groothuis, Marcel Flendrie, Karin H. L. Gerrits, & Sibrand Houtman. (2002). Increased vascular resistance in paralyzed legs after spinal cord injury is reversible by training. Journal of Applied Physiology. 93(6). 1966–1972. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kok Ooi Kong Breakdown of academic impact, for papers by Sophie Pouplin Breakdown of academic impact, for papers by María Pilar Cruz-Domínguez Breakdown of academic impact, for papers by Marion Couderc Breakdown of academic impact, for papers by Han Joo Baek Breakdown of academic impact, for papers by Andy Abril Breakdown of academic impact, for papers by Geun-Tae Kim Breakdown of academic impact, for papers by Socorro Méndez‐Martínez Breakdown of academic impact, for papers by Anestis Mavridis Breakdown of academic impact, for papers by M. Hammoudeh
Rankless by CCL
2026